The Food and Drug Administration approved a new Alzheimer’s drug that has been shown in clinical trials to modestly slow a decline in memory and thinking abilities in people with the disease. The drug donanemab, which will be sold by Eli Lilly under the brand name Kisunla, is now the second treatment option available in the U.S. for the disease.